Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Evoke Pharma (EVOK)

Evoke Pharma (EVOK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 23,020
  • Shares Outstanding, K 24,232
  • Annual Sales, $ 0 K
  • Annual Income, $ -7,570 K
  • 60-Month Beta 1.53
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.19

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.07
  • Number of Estimates 1
  • High Estimate -0.07
  • Low Estimate -0.07
  • Prior Year -0.10
  • Growth Rate Est. (year over year) +30.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.75 +35.10%
on 10/15/19
1.08 -5.49%
on 11/13/19
+0.22 (+27.79%)
since 10/14/19
3-Month
0.73 +39.12%
on 10/11/19
1.10 -7.27%
on 09/17/19
+0.18 (+21.04%)
since 08/14/19
52-Week
0.50 +103.96%
on 06/26/19
3.26 -68.71%
on 02/20/19
-1.63 (-61.51%)
since 11/14/18

Most Recent Stories

More News
Evoke Pharma Granted 180-Day Extension by Nasdaq Regarding Minimum Bid Price

Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that on November 12, 2019, it received notification from...

EVOK : 1.02 (+7.37%)
Evoke Pharma Reports Third Quarter 2019 Financial Results

Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial results for the third quarter ended September...

EVOK : 1.02 (+7.37%)
Foamix Initiates Phase II Study on Acne Combination Foam

Foamix (FOMX) enrolls first patient in phase II study on its topical combination foam, FCD105, for the treatment of moderate-to-severe acne vulgaris.

FOMX : 3.44 (-3.10%)
EVOK : 1.02 (+7.37%)
RDY : 38.28 (-0.80%)
BHC : 27.75 (+1.35%)
Zynerba Releases Data on Epilepsy Candidate, Stock Down

Zynerba (ZYNE) announces positive top-line results from the BELIEVE 1 study evaluating the efficacy and safety of Zygel in a heterogeneous group of rare and ultra-rare epilepsies.

RDY : 38.28 (-0.80%)
AGRX : 2.38 (+10.19%)
ZYNE : 6.11 (-4.68%)
EVOK : 1.02 (+7.37%)
Evoke Pharma Completes Manufacturing of Commercial Scale Registration Batches of Gimoti(TM)

Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it has completed manufacturing commercial scale batches...

EVOK : 1.02 (+7.37%)
Evoke Pharma to Resubmit Gimoti(TM) NDA Based on FDA Meeting Minutes and Announces Second Quarter 2019 Financial Results

Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that following receipt of U.S. Food and Drug Administration...

EVOK : 1.02 (+7.37%)
Evoke Pharma Requests Type A FDA Meeting to Plan for Resubmission of Gimoti(TM) NDA

Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it has submitted a type A meeting request and meeting...

EVOK : 1.02 (+7.37%)
Evoke Pharma Reports First Quarter 2019 Financial Results

Projected cash runway extended to first quarter 2020

EVOK : 1.02 (+7.37%)
Evoke Pharma (EVOK) to Post Q1 Earnings: What's in Store?

During Evoke Pharma's (EVOK) Q1 conference call, investor focus will be on its progress and issues related to the NDA submission for Gimoti to treat diabetic gastroparesis.

ADVM : 9.01 (-0.11%)
MRUS : 15.99 (+0.69%)
RGEN : 81.68 (-1.85%)
EVOK : 1.02 (+7.37%)
Dr. Reddy's (RDY) Inks Deal to Acquire Portfolio of 42 ANDAs

Dr. Reddy's (RDY) inks agreement to acquire the yet-to-be-marketed portfolio of 42 non-marketed Abbreviated New Drug Applications (ANDAs) in the United States.

MNK : 2.79 (-4.12%)
RDY : 38.28 (-0.80%)
EVOK : 1.02 (+7.37%)
BHC : 27.75 (+1.35%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More Share

Trade EVOK with:

Business Summary

Evoke Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. The Company's lead product candidate, EVK-001, is in late stage clinical testing which is intended for the treatment of diabetic gastroparesis. Evoke...

See More

Key Turning Points

2nd Resistance Point 1.09
1st Resistance Point 1.05
Last Price 1.02
1st Support Level 0.96
2nd Support Level 0.91

See More

52-Week High 3.26
Fibonacci 61.8% 2.21
Fibonacci 50% 1.88
Fibonacci 38.2% 1.55
Last Price 1.02
52-Week Low 0.50

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar